HS Code:
The category 'Glands and other organs, dried, whether or not powdered' falls under HS Code 3001. This category includes dried glands and other organs for organo-therapeutic uses, whether or not powdered, as well as extracts of glands or other organs or of their secretions for similar uses. These products are primarily used in the pharmaceutical industry for the production of medicines and therapeutic treatments, such as hormone therapies and other specialized medical applications. The trade of these products is highly regulated due to health, safety, and ethical considerations, often requiring stringent documentation and compliance with international health standards.
Total Trade Volume
Approximately $1.2 billion USD
Data from 2022
Source
United Nations Comtrade Database and World Trade Organization (WTO) reports
$350 million USD
29.2% of total trade of total trade
Increasing
$200 million USD
16.7% of total trade of total trade
Stable
$150 million USD
12.5% of total trade of total trade
Increasing
$100 million USD
8.3% of total trade of total trade
Stable
$80 million USD
6.7% of total trade of total trade
Increasing
Average Rate
5.8% ad valorem
Highest Rate
15% (applied by certain developing countries for protective measures)
Lowest Rate
0% (under free trade agreements such as EU-US trade pacts or within regional blocs like the EU)
Growing demand for organo-therapeutic products
Increased trade volume due to rising global healthcare needs, particularly for hormone-based therapies and treatments for chronic diseases.
2021-2022
Shift towards synthetic alternatives
Potential reduction in demand for natural gland-derived products as synthetic and lab-grown alternatives become more cost-effective and ethically acceptable.
2020-2022
Stringent regulatory frameworks
Higher compliance costs and barriers to entry for smaller exporters, consolidating market share among major players in developed countries.
2019-2022
The European Union introduced stricter guidelines on the import of gland-derived products, mandating detailed traceability and ethical sourcing documentation to prevent illegal trade and ensure patient safety.
March 2023
Increased compliance costs for exporters to the EU, potentially reducing trade volumes from non-compliant countries while favoring established suppliers.
A new bilateral agreement between the US and China includes provisions to ease tariffs on certain pharmaceutical raw materials, including dried glands and organ extracts, to boost supply chain efficiency.
January 2023
Expected increase in trade volume between the two countries, benefiting Chinese exporters and US pharmaceutical manufacturers.
Breakthroughs in synthetic biology have led to the development of lab-produced hormone extracts, challenging the traditional market for natural gland-derived products.
September 2022
Potential long-term decline in demand for natural products, pushing exporters to innovate or diversify their offerings.